Epigenetic modulators and the new immunotherapies
AE Dear - New England Journal of Medicine, 2016 - Mass Medical Soc
New England Journal of Medicine, 2016•Mass Medical Soc
Epigenetic Modulators and the New Immunotherapies | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
A couple of recent studies suggest that DNA methyltransferase inhibitors, currently used in the treatment of hematologic cancers, increase the sensitivity of tumor cells to immune-checkpoint–inhibitor therapy.
The New England Journal Of Medicine